In recent years, studies have found that PAUF also expresses in ovarian cancer samples at varied levels (Kim S. J et al., 2014; Choi et al., 2018), and patients with elevated PAUF expression, compared to those with low PAUF expression, were associated with less favorable treatment outcomes, such as chemotherapy resistance, around 2-fold higher risk of disease progression and death (Kim S. J et al., 2014; Choi et al., 2018). The gene discussed is ZG16B; the disease is ovarian cancer.